Heron Therapeutics Inc
HRTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$137.42M
Close$
$3.67
721.3% upside
Current Fair Value
721.3% upsideUndervalued by 721.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $137.42 Million |
|---|---|
| Enterprise Value | $252.94 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.12 |
| Beta | 1.71 |
| Outstanding Shares | 189,646,000 |
Return
| Return on Equity | -338.63% |
|---|---|
| Return on Assets | -12.57% |
| Return on Invested Capital | -8.39% |
Valuation & Multiples
| P/E Ratio | -5.33 |
|---|---|
| PEG | 1.31 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.68 |
| Enterprise Value to EBIT | -19.37 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.56 |
| Debt to Equity | 15.5 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$36.72 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$42.13 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.8988▲ 183.63% |
|---|---|
| Total Calls | 1,124,200▲ 201.31% |
| Total Puts | 2,134,600▲ 9061.37% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 94.09%▲ 2.24% |
|---|---|
| Total Invested | $125.62M▼ 39.25% |
| Investors Holding | 173▼ 2.00% |
ESG Score
No data
About Heron Therapeutics Inc
CEO: Barry Quart